RecruitingNot ApplicableNCT06972082

Prevention and Treatment of AKI VEXUS Guided Post Cardiac Surgery

Prevention and Treatment of Acute Kidney Injury After Cardiac Surgery Guided by Combined Cardiac and Splanchnic Sonographic Assessment


Sponsor

Onassis Cardiac Surgery Centre

Enrollment

304 participants

Start Date

Jun 29, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The main goal of this clinical trial is to learn if evaluation by ultrasound of venous congestion of liver and kidneys can guide treatment and prevent and treat acute kidney injury post cardiac surgery (CSA-AKI). Participants will: Be evaluated by liver and kidney veins ultrasound (treatment group) or a placebo post CSA-AKI. Fluid management for the treatment group will be based on a score that emerges from this evaluation (Venous Excess Ultrasound Score, VEXUS). Kidney function will be daily monitored and followed-up for 7 days and until discharge. Daily fluid balance and laboratory examination will be performed. Data will be recorded and collected and a statistical analysis will provide the results that will show or not a probable superiority of this evaluation comparing to the usual care.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called VEXUS for people with acute kidney injury and cardiac surgery associated acute kidney injury. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEVEXUS

Goal-directed fluid and drug therapy according to VEXUS measurements to minimize AKI


Locations(1)

Onassis Cardiac Surgery Center

Athens, Kallithea, Greece

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06972082


Related Trials